ORIONS Money Stocks

[TIMGZ]

***EFTR*** TOPLINE REPORT, ROCKING AFTER HOUR SO FAR 64% UP TREND
BRIEF-Effector Therapeutics Reports Positive Data Updates From Phase 2 Expansion Cohorts Evaluating Zotatifin In Patients With Er+ Metastatic Breast Cancer At The Asco 2023 Annual Meeting


* EFFECTOR THERAPEUTICS REPORTS POSITIVE DATA UPDATES FROM PHASE 2 EXPANSION COHORTS EVALUATING ZOTATIFIN IN PATIENTS WITH ER+ METASTATIC BREAST CANCER AT THE ASCO 2023 ANNUAL MEETING

* EFFECTOR THERAPEUTICS(EFTR): PARTIAL RESPONSES IN 26% PATIENTS TREATED WITH ZOTATIFIN 0.07 MG/KG WITH FULVESTRANT & ABEMACICLIB IN HEAVILY PRETREATED POPULATION

* EFFECTOR THERAPEUTICS INC(EFTR): BOTH COMBINATIONS WERE GENERALLY WELL TOLERATED WITH LARGE MAJORITY OF ADVERSE EVENTS GRADE 1 OR 2

* EFFECTOR THERAPEUTICS INC(EFTR): PARTIAL RESPONSE OBSERVED IN 1 OF 3 (33%) PATIENTS TREATED WITH ZOTATIFIN 0.1 MG/KG COMBINED WITH FULVESTRANT (ZF DOUBLET)

* EFFECTOR THERAPEUTICS INC(EFTR): REPORTING DATA FROM COMPLETED DOSE ESCALATION IN SECOND HALF OF 2023